-- 米国は、ベネズエラの主要債券に関連する制裁措置を延長し、債権者が同国の海外資産に担保として差し押さえられるのを遅らせたと、米財務省が月曜日に発表した。 財務省外国資産管理局(OFAC)は、ベネズエラ国営石油会社PdVSAの2020年債に関連する特定の取引を6月19日からのみ許可する一般ライセンス5Wを発行したと発表した。これにより、同債券に関連する執行措置の凍結が延長される。 OFACによると、担保として差し入れられた株式の売却または譲渡、特に米国に拠点を置く石油精製会社シトゴ・ペトロリアムに関連する株式の売却または譲渡は、OFACの承認がない限り、6月19日まで引き続き禁止される。 2019年から続く一連の延長措置の一環として3月に発行された以前のライセンスは、5月5日に期限切れとなる予定だった。 新たなライセンスは最終的に6月19日以降の債券関連取引を許可するものの、他の制裁措置を無効にするものではないため、追加の承認が必要となる場合がある。米財務省外国資産管理局(OFAC)は、債権者とベネズエラがPdVSAの2020年債の再編または借り換えに関する合意に達した場合、関係当事者は特定の許可を取得する必要がある可能性があると述べ、そのような取り決めに対しては有利な許可政策を採用すると付け加えた。 一方、米国はここ数カ月、ベネズエラのエネルギー部門に対する一部の制裁を緩和し、中核的な金融制裁は維持されているものの、PdVSAとの限定的な取引を認めている。
Related Articles
Lottery Secures Agreement for 40-Year License Extension
Lottery (ASX:TLC) secured an agreement with the Victorian State Government for a 40-year extension of the public lottery license, according to a Tuesday filing with the Australian bourse.The license is extended to June 30, 2068, with the company paying an upfront premium of AU$1.15 billion to the state, the filing said.Historically, the license has been offered on 10-year terms and was set to expire on June 30, 2028, per the filing.
Gentrack Group Cuts Fiscal 2026 Revenue Guidance; Plans Buyback; Kiwi Shares Fall 22%
Gentrack Group (NZE:GTK, ASX:GTK) said it now expects fiscal year 2026 revenue of between NZ$229 million and NZ$238 million, lower than its previous guidance, according to a Tuesday filing with the Australian and New Zealand bourses.The company expects fiscal year 2026 recurring revenue to grow by over 10% to around NZ$174 million. It also expects fiscal first-half revenue of around NZ$110 million, of which roughly NZ$85 million would be recurring, per the filing.Gentrack said it expects fiscal year 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) of NZ$13.5 million to NZ$20 million, and fiscal first half EBITDA of about NZ$7.8 million, both excluding acquisition costs.The guidance comes as the company has decided "to prioritize growth and global leadership over short-term EBITDA" and continues to invest in international expansion and product development, it said.The company maintained its medium-term target of a more than 15% compound annual growth rate for revenue.Additionally, after the release of fiscal first-half results, Gentrack's board plans to launch an on-market share buyback for up to 5% of the company's issued shares, per the filing.The company's Kiwi shares fell 22% in recent Tuesday trade on the New Zealand bourse.
Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.